- News
Ceva Santé Animale acquires Scout Bio, paving the way for groundbreaking innovations in pet therapeutics
Libourne, January 25, 2024 – Ceva Santé Animale (Ceva), the #5 animal health company present in 110 countries worldwide, announces the strategic acquisition of Scout Bio, a pioneer in…
- News
Scout Bio to Present at Upcoming Gene and Cell Therapy Summit
PHILADELPHIA, May 19, 2023 (GLOBE NEWSWIRE) | Scout Bio, a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions, today announced that…
- News
Scout Bio Announces Appointment Of Chief Manufacturing Officer
Experienced global animal health biologics executive to drive manufacturing strategies and advance pipeline of multiple animal health monoclonal antibodies (mAbs) and novel adeno-associated virus (AAV) therapeutics. PHILADELPHIA, JULY 1,…
- News
Scout Bio To Present Positive Clinical Data On SB-001 For Feline CKD-Anemia at Leading Veterinary Medicine Forum
Scout Bio’s research was selected for presentation at the American College of Veterinary Internal Medicine (ACVIM) Forum Three lectures will present Scout Bio’s technology, new areas of research, and…
- News
Scout Bio to Feature at Morgan Stanley Animal Health Biopharma Global KOL Summit
Leading veterinary biopharma innovators, experts, and investors in gene therapy technologies, including Aaron Schacht and Mark Heffernan, to present opportunities for therapeutic innovation in rapidly growing market PHILADELPHIA, June…
- News
Scout Bio Appoints Life Sciences Executive Aaron Schacht to Board of Directors
Brings experience in managing global innovation portfolios and business development to Scout Bio Executive leadership experience across both animal and human health PHILADELPHIA, February 18, 2022 – Scout Bio,…
- News
Scout Bio to Present at Upcoming Animal Health Conferences
PHILADELPHIA, February 15, 2022 – Scout Bio, a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions, today announced that it will…
- News
Scout Bio Expands Gene Therapy Collaboration with the University of Pennsylvania Via Next-Generation Vector Technologies
Partnership agreement includes exclusive rights in animal health to novel viral vector capsid and expands additional option rights to novel capsids Next-generation novel adeno-associated viral (AAV) vector capsid promises…
- News
Scout Bio Named Best New Start-Up for 2021
IHS Markit recognizes Scout Bio for pioneering therapies in companion animal medicine PHILADELPHIA, November 08, 2021 — Scout Bio, a biotechnology company focused on one-time AAV gene therapies for…
- News
Scout Bio Initiates Multi-Center Clinical Study of Gene Therapy for Chronic Arthritis Pain In Cats
– First vectorized antibody gene therapy to be studied in pets – Strong initial in-species data support therapeutic profile of one-time gene therapy designed for long-term pain management –…
- News
Scout Bio Closes $33 Million Series B2 Financing to Advance its Portfolio of Single Injection Gene Therapy Technology for the Treatment of Chronic Diseases in Pets
– Proceeds to support advancing single injection Adeno-Associated Viral (AAV) vector therapeutics targeting chronic companion animal diseases including diabetes, pain, and anemia associated with chronic kidney disease (CKD) – New…
- News
Scout Bio to Present at Upcoming October Investor Conferences
PHILADELPHIA, Oct. 04, 2021 (GLOBE NEWSWIRE) — Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic…
- News
Scout Bio Successfully Completes Pilot Clinical Study of SB-001, A Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia
PHILADELPHIA, September 9, 2021 — Scout Bio today announced the successful completion of a CKD-associated anemia study in client owned cats treated with SB-001, an AAV expressing feline erythropoietin (fEPO).…
- News
Scout Bio to Present at Stifel 2021 Virtual Jaws & Paws Conference
PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) — Scout Bio today announced that Mark Heffernan, Chief Executive Officer, will present at the upcoming Stifel 2021 Virtual Jaws & Paws Conference…
- News
Scout Bio to Present at the BofA Securities 2021 Animal Health Summit
PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) – Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions,…
- News
Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes
Two pilot studies initiated to explore clinical applications for this convenient, one-time injectable treatment Positions Scout Bio as the first company to advance novel GLP-1 constructs for gene therapy…
- News
Scout Bio Reports Statistically Significant Clinical Outcomes for Pilot Study of SB-001 for Treatment of CKD-Associated Anemia in Felines
SB-001, a gene therapy expressing feline erythropoietin (fEPO), demonstrates clinically relevant hematocrit improvements in end-stage anemia patients and improved quality of life scores PHILADELPHIA, Sept. 30, 2020 (GLOBE NEWSWIRE)…
- News
Scout Bio to Present at Upcoming October Investor Conferences
PHILADELPHIA, September 28, 2020 – Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic pet health conditions,…
- News
Scout Bio Appoints Clinical Research Leader Dr. Anne Traas as Chief Development Officer
PHILADELPHIA, October 28, 2019 – Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions, today…
- News
Scout Bio Announces $20 Million Financing to Advance Pipeline of One-time Therapies for Companion Animals
Financing to drive leadership in AAV vector-delivered one-time therapies for major chronic pet health conditions Company supported by leading life sciences investors and an R&D collaboration with the Gene…
